The bone marrow microenvironment is an extraordinarily complex niche composed of endothelial cells, mesenchymal stromal populations, adipocytes, and osteogenic lineages, all of which collectively regulate hematopoiesis. Capturing this diversity in vitro has been a long-standing challenge. Existing models often fall short—typically lacking simultaneous lymphopoiesis and myelopoiesis, omitting adipogenic or osteogenic compartments, and suffering from limited scalability. In this context, the recently published ComBO system represents an ambitious attempt to reconstruct a more complete human bone marrow organoid.

The study introduces a combined bone and lympho-myeloid organoid (ComBO) that aims to overcome these limitations. Notably, the system is capable of supporting engraftment of primary multiple myeloma (MM) cells and allows interrogation of disease-induced niche remodeling. This alone marks an important step forward, as primary MM cells are notoriously difficult to maintain in vitro.

The developmental strategy relies on staged exposure to cytokine cocktails and controlled oxygen conditions to guide both stromal and hematopoietic niche formation. Mesoderm induction is followed by hydrogel embedding and a lymphoid induction phase, with IL-7 playing a central role in promoting lymphopoiesis. By day 20–35, co-immunostaining reveals a CD34⁺ endothelial network supported by CD271⁺ stromal cells. Interestingly, lymphoid progenitors (CD7⁺) appear enriched in regions that also exhibit early osteogenic markers such as OCN (BGLAP) and SP7 (OSX). Histological analysis (H&E) suggests formation of bone-like structures, while von Kossa staining demonstrates progressive mineralization over time.

Single-cell RNA sequencing at days 20 and 35 further supports the emergence of a complex and diverse cellular ecosystem. The transcriptional landscape resembles adult rather than fetal bone marrow, with representation of multiple hematopoietic populations—including monocytes/macrophages, neutrophils, dendritic cells, lymphoid and myeloid progenitors, erythroid cells, megakaryocytes, and HSPCs. The stromal compartment is equally diverse, comprising sinusoidal, arterial, and capillary endothelial cells, mesenchymal stromal cells, CXCL12-abundant reticular (CAR) cells, adipocyte/osteoblast lineage cells, and fibroblasts. Importantly, markers associated with more mature hematopoietic states, including T cell signatures, increase between day 20 and day 35, indicating ongoing maturation.

One particularly elegant aspect of the study is the use of granular microgels to enable scalable organoid production. By mechanically processing hydrogels into granular components and compacting them in multiwell plates, the authors achieve high-throughput generation of organoids without compromising cellular or molecular complexity. This represents a practical and potentially widely adoptable advance for organoid systems.

Functionally, the ComBO model demonstrates the ability to support hematopoietic progenitors over extended periods. Serial reseeding experiments show that CD34⁺ cells can be maintained and expanded across multiple organoid passages, retaining the ability to differentiate into both lymphoid and myeloid lineages. Furthermore, T cell progenitors derived from ComBOs can mature into functional T cells when transferred to artificial thymic organoids, underscoring the physiological relevance of the system. Dynamic culture conditions also improve vascular organization, suggesting that perfusion or mechanical cues may further enhance niche functionality.

The model is particularly compelling in the context of disease modeling. When primary CD138⁺ MM cells are introduced, they successfully engraft and proliferate within the organoids. Single-cell RNA-seq and flow cytometry confirm the presence of actively cycling MM cells, alongside widespread remodeling of the microenvironment. Differential abundance and gene expression analyses reveal increased lymphoid progenitors, mast cell populations, early osteolineage cells, adipocytes, and endothelial cells. Gene set enrichment highlights metabolic and inflammatory pathways, while upregulation of chemokines such as CCL2 and stress-related genes like JUNB suggests active niche perturbation.

Importantly, the study captures key features of MM-associated pathology, including enhanced osteoclastogenic signaling and inflammatory activation. Increased S100A8/A9 expression indicates heightened neutrophil activity, and CellChat analysis identifies MIF as a central mediator of MM-driven inflammation. MM cells appear to signal strongly to hematopoietic compartments via MIF, inducing TNF signaling in myeloid cells, while interactions with stromal cells are mediated through SPP1. Pharmacological inhibition or genetic knockout of MIF significantly reduces inflammatory signaling and partially rescues stromal alterations, providing mechanistic insight into disease progression.

Despite these strengths, several aspects of the study warrant closer scrutiny—particularly regarding the osteogenic component, which is one of the central claims of the ComBO system. While early osteogenic markers such as SP7 and later markers like BGLAP are detected, and mineralization is observed by day 80, osteogenesis appears to be delayed and relatively weak at earlier time points (e.g., day 35). This raises the possibility that the system supports gradual, self-organized osteogenic maturation rather than robust, directed osteogenic differentiation.

This interpretation is further supported by the absence of clearly defined osteo-inductive cues in the protocol. Although BMP4 is included, canonical osteogenic drivers such as dexamethasone, β-glycerophosphate, or ascorbic acid are not explicitly used. The reliance on collagen-based hydrogels (as in the authors’ previous non-osteogenic models) suggests that matrix stiffness and mechanical cues may play a role, potentially leading to slower and less synchronized osteogenesis. Over extended culture, cells may remodel their microenvironment sufficiently to permit mineralization, explaining the stronger phenotype observed at later stages.

There are also inconsistencies between the textual claims and the transcriptomic data. For example, markers such as BGLAP, JAG1, and GREM1 are reported as defining osteoblast or osteolineage populations, yet are not clearly evident in the referenced figure. Similarly, TNFSF11 (RANKL) is attributed to osteoclasts in the text, despite being classically expressed by osteoblast-lineage cells. Several markers listed as osteoblast-specific (e.g., SPP1, WNT5A, ANGPT1) are in fact broadly expressed and not lineage-restricted. These discrepancies introduce ambiguity into the interpretation of the osteogenic compartment.

Another important limitation relates to the long-term stability of the stromal niche. While serial reseeding experiments demonstrate maintenance of CD34⁺ progenitors, the need to transfer cells into fresh organoids every two weeks suggests that the niche itself may not be stable over extended periods. This is consistent with flow cytometry data showing a decline in endothelial populations between day 20 and day 35. Moreover, the absence of in vivo transplantation experiments leaves open the question of whether these CD34⁺ cells possess true long-term repopulating capacity.

Finally, while the study provides a detailed analysis of MM-induced niche remodeling, it does not deeply explore how MM affects osteogenic pathways specifically. Changes in key osteogenic regulators such as RUNX2 are shown but not discussed in depth, leaving a gap in understanding how the disease impacts bone formation within this system.

Overall, the ComBO model represents a technically impressive and conceptually important advance in bone marrow organoid biology. Its ability to support both lymphopoiesis and myelopoiesis, combined with scalability and disease modeling capacity, makes it a valuable platform for preclinical research. However, the osteogenic component—while present—appears less well-defined and mechanistically underexplored. Future work clarifying the drivers of osteogenesis and improving niche stability would further strengthen this already promising system.

In summary, this is a beautifully executed study with particular strength in modeling hematopoietic complexity and disease interactions. The claims regarding osteogenesis are intriguing but would benefit from deeper mechanistic and transcriptional validation.